Sources

5 Total Sources

Arrowhead Pharma Jumps 21% After Plozasiran Trial Cuts Triglycerides, Lifting Target to $115

Right100%

pluang.com1d ago

Arrowhead Pharma Stock Jumps Over 21% on Positive Plozasiran Trial Results

Seeking Alpha1d ago

Arrowhead Pharmaceuticals' Plozasiran Achieves Late-Stage Trial Win for Severe Hypertriglyceridemia

MD Magazine1d ago

Plozasiran Meets Primary Endpoint in SHASTA-3, SHASTA-4 sHTG Trials | HCPLive

GuruFocus.com1d ago

Arrowhead Pharmaceuticals (ARWR) Achieves Late-Stage Trial Succe

Managed Healthcare Executive1d ago

Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia | Managed Healthcare Executive